Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

Abstract Background & aims The NAPOLI 3 trial demonstrated that compared to the nab-paclitaxel and gemcitabine (GemNab) regimen, the NALIRIFOX (5-fluorouracil, leucovorin, liposomal irinotecan, oxaliplatin) regimen can significantly improve patients' overall survival (OS) and progression-fr...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenjie Liu, Yuting Fang, Chao Zhang, Midan Xiang, Lijuan Qi, Aijiang Su, Yongkun Sun
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Gastroenterology
Subjects:
Metastatic pancreatic ductal adenocarcinoma
NALIRIFOX
Nab-paclitaxel and gemcitabine
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12876-025-03867-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12876-025-03867-2

Similar Items